Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma
Wataru Fukuokaya(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Jun Miki(Jikei University School of Medicine), Yuhei Koike(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Shutaro Yamamoto, Shunsuke Tsuzuki(Jikei University School of Medicine), Yu Imai(Jikei University School of Medicine), Hirokazu Abe(Kameda Medical Center), Masaki Hashimoto(The University of Tokyo), Yu Oyama(Kameda Medical Center), Kagenori Ito(Jikei University School of Medicine), Hajime Onuma(Jikei University School of Medicine), Shoji Kimura(Jikei University School of Medicine)
Cited by 5
Related Papers
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282
Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis
|World Journal of Urology|2019|134
Beiging of perivascular adipose tissue regulates its inflammation and vascular remodeling
|Nature Communications|2022|130
Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
|Clinical Cancer Research|2019|129